The Claim
In adults with overweight or obesity (BMI 27–39.9 kg/m²), once-weekly subcutaneous administration of petrelintide at a target dose of 4.8 mg for 8 weeks resulted in a mean body weight reduction of 8.6% after 16 weeks, which was significantly greater than the 1.7% reduction observed with placebo.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with overweight or obesity, a weekly injection of petrelintide for 8 weeks led to an average weight loss of 8.6% after 16 weeks, compared to a 1.7% weight loss with a placebo.
See the scientific wording
In adults with overweight or obesity (BMI 27–39.9 kg/m²), once-weekly subcutaneous administration of petrelintide at a target dose of 4.8 mg for 8 weeks resulted in a mean body weight reduction of 8.6% after 16 weeks, significantly greater than the 1.7% reduction observed with placebo, suggesting petrelintide has clinically relevant weight-loss effects in this population.
A synthetic hormone binds to receptors in the brain that signal fullness, stops the stomach from emptying too quickly, and reduces the release of a hormone that raises blood sugar. This causes people to eat less and absorb fewer calories, leading to loss of body weight over time.
What the research says
1 studyIn a study, people with extra weight got a weekly shot of a drug called petrelintide, and on average, they lost 8.6% of their body weight — much more than those who got a fake shot (only 1.7% loss). This shows the drug really helps with weight loss.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.